Doravirine/lamivudine/tenofovir

Doravirine/lamivudine/tenofovir, sold under the brand name Delstrigo, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS.^[5][7] It contains doravirine, lamivudine, and tenofovir disoproxil.^[8][7] It is taken by mouth.^[5]

Doravirine/lamivudine/tenofovir

Combination of
Doravirine	Non-nucleoside reverse transcriptase inhibitor
Lamivudine	Nucleoside reverse transcriptase inhibitor
Tenofovir disoproxil	Nucleotide reverse transcriptase inhibitor
Clinical data
Trade names	Delstrigo
Other names	MK-1439A
AHFS/Drugs.com	Monograph
MedlinePlus	a618049
License data	US DailyMed: Delstrigo
Routes of administration	By mouth
ATC code	J05AR24 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only[1][2] UK: POM (Prescription only)[3] US: WARNING[4]Rx-only[5] EU: Rx-only[6]
Identifiers
CAS Number	2446159-50-6
KEGG	D11396

In the United States, it was approved by the Food and Drug Administration (FDA) for the treatment of HIV-1 infection in August 2018.^[8][9][10]

References

1. "PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION : DELSTRIGO" (PDF). Pdf.hres.ca. Retrieved 5 June 2022.
2. "Drug and medical device highlights 2018: Helping you maintain and improve your health". Health Canada. 14 October 2020. Retrieved 17 April 2024.
3. "Delstrigo 100 mg /300 mg /245 mg film-coated tablets - Summary of Product Characteristics (SmPC)". Medicines.org.uk. 8 July 2020. Retrieved 1 October 2020.
4. "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
5. "Delstrigo- doravirine, lamivudine, and tenofovir disoproxil fumarate tablet, film coated". DailyMed. 10 October 2019. Retrieved 31 July 2020.
6. "Delstrigo EPAR". European Medicines Agency (EMA). Retrieved 1 October 2020.
7. Canadian Agency for Drugs and Technologies in Health (June 2019). "Common Drug Review New Combination Product: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination (Delstrigo)". CADTH Common Drug Reviews. Ottawa (ON). PMID 31393687.
8. "FDA Approves Merck's Delstrigo (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and Pifeltro (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients" (Press release). Merck & Co. 30 August 2018.
9. "Delstrigo approval letter" (PDF). Food and Drug Administration (FDA). 30 August 2018. Retrieved 10 September 2019.
10. "Drug Approval Package: Pifeltro (doravirine)". U.S. Food and Drug Administration (FDA). 9 October 2018. Retrieved 22 September 2020.

External links

• "doravirine lamuvidine tenofovir disoproxil fumarate". Canadian Agency for Drugs and Technologies in Health (CADTH).